UBS has initiated coverage on Solventum Corp (SOLV) with a Neutral rating as of September 30, 2025. This marks the firm's first assessment of the company's investment merit, reflecting its analysis of Solventum's business, industry dynamics, and growth prospects.
Headquartered in St. Paul, Minnesota, Solventum Corp operates in the health care sector and employs 22,000 full-time employees. The company went public on March 26, 2024. Its segments include MedSurg, Dental Solutions, and Health Information Systems, providing a range of products and services from wound care to dental and software solutions.
Currently, Solventum's stock is priced at $83.23, with a market cap of $13.4 billion. The company has a P/E ratio of 8.80 and an EPS of 8.69. Upcoming earnings reports are expected on May 6, 2026, with an EPS estimate of $1.51 and revenue of $2.0 billion, followed by another report on August 5, 2026, with an EPS estimate of $1.67 and revenue of $2.1 billion.
Analyst ratings and price targets are based on professional research and financial models. They can provide useful perspectives but reflect assumptions that may not materialize. Investment decisions should be informed by a range of factors, including company fundamentals and market conditions. Analyst opinions can change as new information emerges, and different analysts may have varying views on the same company.